==========================
                        JeffNEWS, January 10, 1995
                        ==========================


Behavioral Epidemiology, Bone Marrow Transplant Experts Join
Jefferson Cancer Center
------------------------------------------------------------

Experts in the field of allogeneic bone marrow transplants and in the
behavioral epidemiology of cancer are among the newest cancer
specialists appointed to the staff of the Jefferson Cancer Center.

Neal Flomenberg, MD, most recently director of the bone marrow
transplant program at the Medical College of Wisconsin, joined the
faculty of Jefferson Medical College as professor of medicine with the
division of neoplastic diseases, and serves as director of the bone
marrow transplant and leukemia/lymphoma programs within the Jefferson
Cancer Center. A primary area of Dr. Flomenberg's research is with
allogeneic bone marrow transplants, which are transplants in which donor
and recipient are unrelated and/or substantially mismatched.

A graduate of Pennsylvania State University and Jefferson Medical
College, Dr. Flomenberg completed his internship and residency in
medicine at Bronx Municipal Hospital Center/Albert Einstein College of
Medicine. He was a fellow in hematologic oncology at Memorial Hospital
for Cancer and Allied Diseases in New York, and a research fellow and
research associate at Sloan-Kettering Institute for Cancer Research in
New York.

Named as head of behavioral epidemiology at the Jefferson Cancer Center
is Ronald E. Myers, PhD, who came to Jefferson from Fox Chase Cancer
Center, where he was Associate Member of the Division of Population
Science. Myers received BS and Master's Degrees from Shippensburg
University in Pennsylvania, and a DSW in social welfare and PhD in
sociology from the University of Pennsylvania. He is a consultant to the
Southwest Oncology Group and co-chairman of the health practices
research committee of the Eastern Cooperative Oncology Group. His main
areas of interest are the social epidemiology of disease prevention in
high-risk populations, health practices research, policy analysis and
program evaluation.

Also named to the Division of Neoplastic Diseases at Jefferson is David
Michael Friedland, MD, most recently with the University of Pennsylvania
Cancer Center at the Hospital of the University of Pennsylvania. Dr.
Friedland received BS and MD degrees from the University of Maryland,
and completed postgraduate training at the University of Pittsburgh
Medical Center and at the Hospital of the University of Pennsylvania,
where he was a fellow in the division of hematology/oncology. Primary
areas of research for Dr. Friedland are lung cancer and genitourinary
oncology.

"The addition of these outstanding professionals will greatly enhance
our ability to translate scientific discovery into clinical action,"
said Robert L. Comis, MD, director of clinical programs for the
Jefferson Cancer Center and the Jefferson Cancer Network.  	

The Jefferson Cancer Network is a consortium of seven hospitals in the
Delaware Valley that combine the resources of their cancer specialists
to provide patients at each member institution access to the latest
developments in cancer research, technology and treatments. The
hospitals are Jefferson, Chestnut Hill Hospital, Wills Eye Hospital,
Grand View Hospital, Methodist Hospital, Lower Bucks Hospital and A. I.
duPont Institute in Wilmington, Delaware.


------------------------------------------------------------------------------
Information provided by:  Editor, JeffNEWS
                          (215) 955-6204
------------------------------------------------------------------------------